作者: Franz Rödel , Panagiotis Balermpas
DOI: 10.21037/6977
关键词:
摘要: Squamous cell carcinoma of the head and neck region (HNSCC) is sixth important tumour entity by incidence worldwide associated with more than 300,000 HNSCC related deaths/year (1). Current standard treatment, especially in advanced situation, comprises definitive cisplatinum based chemoradiation therapy (CRT) or adjuvant CRT after surgical resection patients high risk tumours (2). Prognosis, however, remains poor for entire 5-year survival rates around 50% (3).